Versartis Inc (NASDAQ:VSAR) insider Jay Shepard sold 14,446 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $1.80, for a total transaction of $26,002.80. Following the completion of the sale, the insider now owns 602,298 shares of the company’s stock, valued at approximately $1,084,136.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Versartis Inc (NASDAQ VSAR) opened at $1.72 on Wednesday. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.11. Versartis Inc has a twelve month low of $1.60 and a twelve month high of $24.00. The firm has a market cap of $61.77, a PE ratio of -0.44 and a beta of 2.11.
VSAR has been the subject of several recent analyst reports. Cantor Fitzgerald set a $14.00 price objective on shares of Versartis and gave the company a “buy” rating in a research note on Friday, October 27th. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $5.63.
A number of large investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC increased its holdings in Versartis by 1.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 32,597 shares of the biopharmaceutical company’s stock valued at $569,000 after acquiring an additional 535 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Versartis by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 109,409 shares of the biopharmaceutical company’s stock valued at $1,910,000 after acquiring an additional 627 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Versartis by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock valued at $459,000 after acquiring an additional 1,204 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Versartis by 2.2% during the 2nd quarter. Goldman Sachs Group Inc. now owns 103,044 shares of the biopharmaceutical company’s stock valued at $1,798,000 after acquiring an additional 2,260 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. grew its holdings in shares of Versartis by 13.6% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 24,714 shares of the biopharmaceutical company’s stock worth $431,000 after buying an additional 2,967 shares in the last quarter. Hedge funds and other institutional investors own 48.73% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/14/jay-shepard-sells-14446-shares-of-versartis-inc-vsar-stock.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.